

# GPI WEB CLIENT

[Help](#)
[Comments](#)
[Logout](#)
[Main Menu](#) [Search Form](#) [Posting Counts](#) [Show S Numbers](#) [Edit S Numbers](#)

## Search Results - 158 Hits.

Term	Occurrence
LEVODOPA/BI AND CARBIDOPA/BI	8
LEVODOPA/BI	16
CARBIDOPA/BI	12

Database: [US, Japanese and European Patents](#) ▼

[Refine Search:](#)
[#S2162](#)

## Search History

DB Name	Query	Hit Count	Set Name	Time
EPO	(same as L12)	8	<a href="#">L13</a>	Mon Aug 31 14:31:39 1998
JPO	(same as L11)	0	<a href="#">L12</a>	Mon Aug 31 14:31:38 1998
USPAT	#S2162	150	<a href="#">L11</a>	Mon Aug 31 14:31:37 1998
USPAT	5387612	3	<a href="#">L10</a>	Mon Aug 31 14:04:52 1998
USPAT	#L4	150	<a href="#">L9</a>	Mon Aug 31 13:35:23 1998
USPAT	#L4	0	<a href="#">L8</a> ▲	Mon Aug 31 13:35:22 1998
EPO	#L6	8	<a href="#">L7</a>	Mon Aug 31 13:32:27 1998
EPO	(same as L5)	8	<a href="#">L6</a>	Mon Aug 31 13:32:18 1998
JPO	(same as L4)	0	<a href="#">L5</a>	Mon Aug 31 13:32:18 1998
USPAT	LEVODOPA AND CARBIDOPA	150	<a href="#">L4</a>	Mon Aug 31 13:32:17 1998
EPO	(same as L2)	16	<a href="#">L3</a>	Mon Aug 31 13:32:07 1998
JPO	(same as L1)	2	<a href="#">L2</a>	Mon Aug 31 13:32:06 1998
USPAT	LEVODOPA	378	<a href="#">L1</a>	Mon Aug 31 13:32:06 1998

# GPI WEB CLIENT

[Help](#)
[Comments](#)
[Logout](#)

Main Menu	Search Form	Result Set	Show S Numbers	Edit S Numbers	First Hit
Previous Patent	Next Patent	Show Annotations	Add Annotation		
Front	Citation	Pub	Cls		

WO009212710A1

Aug. 6, 1992

L7: 2 of 8

ORALLY ADMINISTERABLE DRUGS FOR THE TREATMENT OF CENTRAL DOPAMINE DEFICIENCY CONDITIONS

INVENTOR: WENZEL, UDO (DE)  
 WEBER, GUENTHER (DE)  
 METZNER, JUERGEN (DE)  
 DAERR, ALFRED (DE)  
 FREITAG, SABINE (DE)  
 FLOETHER, FRANK-ULRICH (CH)  
 ALBERT, FRANK-MICHAEL (DE)  
 HAASE, MARGIT (DE)  
 LEISTNER, EDITH (DE)

APPLICANT: ISIS CHEMIE GMBH (DE)

APPL NO: DE 09200043

DATE FILED: Jan. 23, 1992

PRIOR-AP: DE 04101873A Jan. 23, 1991

INT-CL: A61K9/16; A61K9/20; A61K31/195


EUR-CL: A61K9/16; A61K9/20; A61K31/195

## ABSTRACT:

The invention concerns an orally administerable drug formulation and a method of preparing it, in which the drugs levodopa and carbidopa are embedded in defined proportions in a hydrophilic substrate consisting of a mixture of poly(vinyl alcohol) polymers of different vinyl acetate content and non-toxic auxiliaries. This formulation considerably increases the effectiveness of the treatment of central dopamine deficiency conditions, in particular in Parkinson's disease, by ensuring that therapeutically effective blood values are maintained in the release phase.

Main Menu	Search Form	Result Set	Show S Numbers	Edit S Numbers	First Hit
Previous Patent	Next Patent	Show Annotations	Add Annotation		
Front	Citation	Pub	Cls		

[Help](#)
[Comments](#)
[Logout](#)

 Z39.50 Gateway Based on CNIDR Isite

## GPI WEB CLIENT

[Help](#)[Comments](#)[Logout](#)

Main Menu	Search Form	Result Set	Show S Numbers	Edit S Numbers	First Hit
Previous Patent	Next Patent	Show Annotations	Add Annotation		
Front	Citation	Pub	Cls		

EP000451484A1

Oct. 16, 1991

L7: 3 of 8

Deprenyl/L-dopa/ carbidopa pharmaceutical composition.

INVENTOR: BRZECZKO, ALBERT WALTER (US)  
NIBBELINK, DONALD WILFRED (US)  
MOLLIKA, JOSEPH A (US)

APPLICANT: DU PONT MERCK PHARMA (US)

APPL NO: EP 91102994

DATE FILED: Feb. 28, 1991

PRIOR-AP: US 50696790A Feb. 28, 1990

INT-CL: A61K31/195


EUR-CL: A61K31/195

### ABSTRACT:

Disclosed are pharmaceutical combination products useful for the treatment of Parkinson's disease. These products are based on a combination of active ingredients which are carbidopa , levodopa , deprenyl in a pharmaceutical carrier, preferably a carrier wherein one or more of the active ingredients are in a sustained release oral dosage formulation.

Main Menu	Search Form	Result Set	Show S Numbers	Edit S Numbers	First Hit
Previous Patent	Next Patent	Show Annotations	Add Annotation		
Front	Citation	Pub	Cls		

[Help](#)[Comments](#)[Logout](#)

 Z39.50 Gateway Based on CNIDR Isite

**GPI WEB CLIENT**[Help](#)[Comments](#)[Logout](#)

Main Menu	Search Form	Result Set	Show S Numbers	Edit S Numbers	First Hit
Previous Patent	Next Patent	Show Annotations	Add Annotation		
Front	Citation	Pub	Cls		

US004983400A

Jan. 8, 1991

L7: 4 of 8


Controlled release combination of carbidopa / levodopa

INVENTOR: DEMPSKI, ROBERT E (US)  
SCHOLTZ, EDWARD C (US)  
NIBBELINK, DONALD W (US)  
REINES, SCOTT A (US)  
APPLICANT: MERCK & CO INC (US)  
APPL NO: US 44422289  
DATE FILED: Dec. 1, 1989  
PRIOR-AP: US 44422289A Dec. 1, 1989  
INT-CL: A61K9/22; A61K9/26; A61K31/78  
EUR-CL: A61K9/20; A61K9/20; A61K31/19; A61K31/195

## ABSTRACT:

A matrix or monolithic drug delivery system for the controlled release of carbidopa and levodopa consists of the two drugs uniformly dispersed in a polymer vehicle at a concentration that is greater than the solubility of either drug in the polymer. Treatment of parkinsonism with the controlled release formulation provides several advantages over treatment with the standard carbidopa / levodopa combination presen employed.

Main Menu	Search Form	Result Set	Show S Numbers	Edit S Numbers	First Hit
Previous Patent	Next Patent	Show Annotations	Add Annotation		
Front	Citation	Pub	Cls		

[Help](#)[Comments](#)[Logout](#) Z39.50 Gateway Based on CNIDR Isite

**GPI WEB CLIENT**[Help](#)[Comments](#)[Logout](#)[Main Menu](#) [Search Form](#) [Posting Counts](#) [Show S Numbers](#) [Edit S Numbers](#)**Search Results - Records 1 through 8 of 8 returned.**[Generate Result Set](#)

1. WO009513803A1, May 26, 1995, BLOCKING INDUCTION OF  
TETRAHYDROBIOPTERIN TO BLOCK INDUCTION OF NITRIC OXIDE SYNTHESIS; GROSS,  
STEVEN S,

INT-CL: [6] A61K31/195; [6] A61K31/495

EUR-CL: A61K31/40; A61K31/505; A61K31/505

1. ☐ [Front](#) [Citation](#) [Pub](#) [Cls](#)

2. WO009212710A1, Aug. 6, 1992, ORALLY ADMINISTERABLE DRUGS FOR THE  
TREATMENT OF CENTRAL DOPAMINE DEFICIENCY CONDITIONS; WENZEL, UDO (DE),  
et al.,

INT-CL: A61K9/16; A61K9/20; A61K31/195

EUR-CL: A61K9/16; A61K9/20; A61K31/195

2. ☐ [Front](#) [Citation](#) [Pub](#) [Cls](#)

3. EP000451484A1, Oct. 16, 1991, Deprenyl/L-dopa/ carbidopa  
pharmaceutical composition.; BRZECZKO, ALBERT WALTER (US), et al.,

INT-CL: A61K31/195

EUR-CL: A61K31/195

3. ☐ [Front](#) [Citation](#) [Pub](#) [Cls](#)

4. US004983400A , Jan. 8, 1991, Controlled release combination of  
carbidopa / levodopa ; DEMPSKI, ROBERT E (US), et al.,

INT-CL: A61K9/22; A61K9/26; A61K31/78

EUR-CL: A61K9/20; A61K9/20; A61K31/19; A61K31/195

4. ☐ [Front](#) [Citation](#) [Pub](#) [Cls](#)

5. US004900755A , Feb. 13, 1990, Controlled release combination of carbidopa / levodopa ; DEMPSKI, ROBERT E (US), et al.,  
INT-CL: A61K9/20; A61K9/22; A61K9/26  
EUR-CL: A61K9/20; A61K9/20; A61K31/19; A61K31/195

5. ☐ Front Citation Pub Cls

6. EP000320051A1, Jun. 14, 1989, Controlled release combination of carbidopa / levodopa .; DEMPSKI, ROBERT E, et al.,  
INT-CL: A61K9/22; A61K9/26; A61K31/19; A61K31/195  
EUR-CL: A61K31/19; A61K31/195; A61K9/20; A61K9/20

6. ☐ Front Citation Pub Cls

7. EP000282206A1, Sep. 14, 1988, Arylcyclobutylalkylamine-derivative for the treatment of Parkinson's disease.; REES, JOHN ANDREW,  
INT-CL: A61K31/135; A61K31/195; A61K31/215; A61K31/33; A61K31/395  
EUR-CL: A61K31/135; A61K31/195; A61K31/215; A61K31/33; A61K31/395;  
A61K31/15; A61K31/215; A61K31/33; A61K31/395

7. ☐ Front Citation Pub Cls

8. EP000253490A1, Jan. 20, 1988, Controlled release combination of carbidopa / levodopa .; DEMPSKI, ROBERT E, et al.,  
INT-CL: [4] A61K9/22  
EUR-CL: A61K31/195; A61K9/20; A61K9/20

8. ☐ Front Citation Pub Cls

Generate Result Set

Term	Occurrence
LEVODOPA/BI AND CARBIDOPA/BI	8
LEVODOPA/BI	16
CARBIDOPA/BI	12

Show 10 More Patents

Starting At: 1

Display Format: B

Main Menu Search Form Posting Counts Show S Numbers Edit S Numbers